Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "THC receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Modulators of retinoid-related orphan receptor gamma
InactiveUS8389739B1Increase the number ofImproving immunogenicityBiocideSteroidsRetinoid-Related Orphan Receptor-GammaRetinoid-Related Orphan Receptor
Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor γ (RORγ) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and / or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of RORγ results in stimulation of TH-17 cell function and / or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
Owner:ORPHAGEN PHARMA INC
Small molecule antagonists of the apelin receptor for the treatment of disease
InactiveUS20140005181A1BiocideOrganic chemistryTHC receptorErythropoietin-producing hepatocellular (Eph) receptor
Owner:SANFORD BURNHAM MEDICAL RES INST
GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
InactiveUS20120021979A1Reducing a subject's dependence on an addictive substanceReduce chanceBiocideNervous disorderAddictive drugsTHC receptor
The present invention involves the use of GLP-1 and its analogs or GLP-1 receptor agonists to modulate dopamine transporter signaling. The implications of this ability include the use of MT-1 and its analogs or GLP-1 receptor agonists, such as exendin-4, to blunt behavioral response to addictive drugs, to decrease drug dependence, to prevent drug abuse relapse, and to treat brain disorders such as neuropsychiatric disorders including ADHD. The present invention also involves the use of GLP-1 and its analogs or GLP-1 receptor agonists to activate GLP-1R in penile tissue, such as for the treatment of erectile dysfunction either as a monotherapy or in combinations with other treatments, such as PDE 5 inhibitors.
Owner:VANDERBILT UNIV
A3 adenosine receptor agonists and antagonists
Disclosed are (N)-methanocarba adenine nucleosides of formulas (I)-(V), for example, of formula (V):as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Benzothiophene-based selective estrogen receptor downregulators
ActiveUS20170166550A1Prevent relapseHigh activityOrganic active ingredientsOrganic chemistryMedical disorderTHC receptor
This invention is benzothiophene-based estrogen receptor downregulators and their compositions and uses to treat estrogen-related medical disorders.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Ligands for nicotinic acetylcholine receptors, and methods of making and using them
InactiveUS8030300B2Easily determining tailoringSimple designBiocideNervous disorderDiseaseAlcoholisms
One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Sigma receptor inhibitors
Owner:ESTEVE PHARMA SA
2-aminopyrimidine modulators of the histamine H4 receptor
Owner:JANSSEN PHARMA NV
Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I):wherein R1, R2, R3, and a are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
![Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists](https://images-eureka.patsnap.com/patent_img/42982c0c-3451-463f-9cda-bd5af31ec6a5/US07902221-20110308-C00001.png "Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists")
![Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists](https://images-eureka.patsnap.com/patent_img/42982c0c-3451-463f-9cda-bd5af31ec6a5/US07902221-20110308-C00002.png "Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists")
![Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists](https://images-eureka.patsnap.com/patent_img/42982c0c-3451-463f-9cda-bd5af31ec6a5/US07902221-20110308-C00003.png "Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists")
Owner:THERAVANCE BIOPHARMA R&D IP LLC
Non-steroidal compounds for androgen receptor modulation
InactiveUS20120041046A1Reduce severityReduce morbidityBiocideCarboxylic acid nitrile preparationAndrogenTHC receptor
Owner:INST SCIO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI I R S T
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
InactiveCN106132422AAntibacterial agentsBacterial antigen ingredientsAdoptive cellular therapyDendritic cell
The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR gamma) and provides adoptive cellular therapies using an agonist of ROR gamma, populations of lymphocyte cells that have been exposed to an agonist of ROR gamma, populations of dendritic cells that have been exposed to an agonist of ROR gamma, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and / or dendritic cells in a patient by administering an agonist of ROR gamma to a patient.
Owner:LICELLA PTY LTD
Alpha 7 nicotinic receptor selective ligands
The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Inhibitors of p75 receptor and their uses
Novel p75 receptor antagonist compounds and compositions and uses thereof for the prevention and treatment of p75-associated disorders, such as neurodegenerative diseases, are described.
Owner:SARAGOVI HORACIO URI
Modulators of retinoid-related orphan receptor gamma
InactiveUS20130150333A1Increase the number ofImproving immunogenicityBiocidePeptide/protein ingredientsRetinoid-Related Orphan ReceptorRetinoid-Related Orphan Receptor-Gamma
Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor γ (RORγ) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and / or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of RORγ results in stimulation of TH-17 cell function and / or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
Owner:ORPHAGEN PHARMA INC
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and / or AP-1, and / or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.
Owner:BRISTOL MYERS SQUIBB CO
Sphingosine 1-phosphate receptor antagonists
InactiveUS9663511B2Improve featuresImproved pharmacokinetic parametersOrganic active ingredientsSenses disorderChronic heart diseaseDiabetic retinopathy
The present invention relates to sphingosine-1-phosphate (S1P) receptors and compounds of the general formula:that are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1-phosphate receptor 2 (S1P2) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1P2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis / scleroderma. The S1P2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.
Owner:ARROYO BIOSCI L L C
3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands
![3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands](https://images-eureka.patsnap.com/patent_img/17ab4f99-48d9-4a68-83de-d901c834edbf/US08802694-20140812-D00001.png "3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands")
![3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands](https://images-eureka.patsnap.com/patent_img/17ab4f99-48d9-4a68-83de-d901c834edbf/US08802694-20140812-D00002.png "3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands")
![3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands](https://images-eureka.patsnap.com/patent_img/17ab4f99-48d9-4a68-83de-d901c834edbf/US08802694-20140812-D00003.png "3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands")
Owner:TARGACEPT INC
Minoxidil for suppressing androgen receptor function
ActiveUS20160045499A1Suppression problemSuppress functionBiocideHydroxy compound active ingredientsTHC receptorProphylactic treatment
Methods for treating androgen receptor related diseases and suppressing androgen receptor related function by administering an effective amount of minoxidil are provided. Methods for treating or prophylactically treating acne by administering an effective amount of minoxidil are also provided. An anti-acne medication is optionally administered to treat or prophylactically treat acne.
Owner:CHUNG GUNG MEDICAL FOUNDATION LINKOU BRANCH +1
Azaindole retinoic acid receptor-related orphan receptor modulators and uses thereof
Provided herein are compounds of the formulas (I) and (II):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Owner:INNOV17
Reversed biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
InactiveUS20130079271A1Minimize adverse side effectReduce usageBiocideOrganic chemistryTHC receptorAdrenergic receptor agonists
In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
Owner:MCCORMICK KEVIN D +9
Nicotinic receptor compounds
Provided herein are compounds and methods of preparation of compounds that are capable of functioning as agonists or antagonists of a nicotinic receptor. Also provided are pharmaceutical compositions comprising one or more of these compounds, which may further comprise one or more additional therapeutic agents. Further provided are methods of treatment of various conditions that may be responsive to such activity at the nicotinic receptors, such as nicotine dependence.
Owner:RES TRIANGLE INST
Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors
ActiveUS8546435B2Good metabolic stabilityImprove bioavailabilityBiocideNervous disorderAdipogenesisTriazole derivatives
The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and / or long term regulation of energy balance, short-, medium-, and / or long term regulation (stimulation and / or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and / or obesity, body weight gain and / or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and / or gastrectomy (ghrelin replacement therapy).
Owner:AETERNA ZENTARIS GMBH +3
Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands
InactiveUS20110257168A1High affinityOrganic active ingredientsNervous disorderTHC receptorAcetylcholine
The present invention relates to compounds of formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
Owner:TARGACEPT INC
Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
InactiveUS8450374B2Decreasing androgen receptor expressionReduce overexpressionBiocideOrganic active ingredientsTHC receptorBiological activation
Owner:UNIVERSITY OF DELAWARE
Amide derivatives as neuropeptide y5 receptor ligands
Disclosed are a series of neuropeptide Y Y5 receptor ligands, and as such are useful to treat disorders related to mood, stress, ADHD, cognition, stress and dementia.
Owner:H LUNDBECK AS
Thyroid receptor ligands
InactiveUS20110301200A1Useful in treatmentBiocideOrganic chemistryThyroid hormone receptor betaTHC receptor
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta (TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.
Owner:CADILA HEALTHCARE LTD
Nicotinic receptor compounds
Compounds and compositions for promoting smoking cessation or decreasing tobacco use or nicotine addiction are provided. The compounds are 2′-fluoro-3′-(substituted phenyl) deschloroepibatidine analogs. The compounds have been found to modulate neuronal nicotine acetylcholine receptors and are useful in methods for the treatment of conditions or disorders influenced by the modulation of neuronal nicotinic acetylcholine receptors.
Owner:RES TRIANGLE INST +2
Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
There are disclosed a series of quinuclidines having the Formula (I), which bind to the nicotinic α7 receptor and may be useful for the treatment of disorders of the central nervous system.
Owner:BRISTOL MYERS SQUIBB CO
Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
Owner:MERCK SHARP & DOHME CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com